UK markets closed

Galapagos NV (GLPG.AS)

Amsterdam - Amsterdam Delayed price. Currency in EUR
Add to watchlist
51.21-0.13 (-0.25%)
At close: 5:35PM CEST
Full screen
Previous close51.34
Bid0.00 x 0
Ask0.00 x 0
Day's range50.44 - 51.57
52-week range48.01 - 166.10
Avg. volume489,399
Market cap3.355B
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)-3.76
Earnings date05 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est115.91
  • Here's Why Galapagos Stock Is Falling Today
    Motley Fool

    Here's Why Galapagos Stock Is Falling Today

    Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday. Following the implosion of Jyseleca in the U.S., Galapagos has leaned on its early clinical-stage pipeline to get attention from investors.

  • Galapagos (GLPG) Falls on Inflammatory Study Data Readout

    Galapagos (GLPG) Falls on Inflammatory Study Data Readout

    Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

  • Globe Newswire

    Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Generally safe and well toleratedPositive efficacy signal in psoriasis patients at Week 440% of patients showed improvement of at least 50% in PASI response (PASI 50) with high dose of GLPG3667 at Week 4Data support initiation of Phase 2b dose finding study in psoriasis Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patient